▶ 調査レポート

世界の化学療法による悪心&嘔吐治療市場規模・現状・予測(2021年-2027年)

• 英文タイトル:Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, Status and Forecast 2021-2027

QYResearchが調査・発行した産業分析レポートです。世界の化学療法による悪心&嘔吐治療市場規模・現状・予測(2021年-2027年) / Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, Status and Forecast 2021-2027 / QFJ1-5654資料のイメージです。• レポートコード:QFJ1-5654
• 出版社/出版日:QYResearch / 2021年6月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、115ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査レポートでは、化学療法による悪心&嘔吐治療の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(アロキシ(パロノセトロン)、キトリル(グラニセトロン)、エメンド(アプレピタント)、その他)、用途別市場規模(急性悪心&嘔吐治療、遅発性悪心&嘔吐治療、予期性悪心&嘔吐治療)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・化学療法による悪心&嘔吐治療の市場動向
・企業の競争状況、市場シェア
・化学療法による悪心&嘔吐治療の種類別市場規模と予測2016-2027(アロキシ(パロノセトロン)、キトリル(グラニセトロン)、エメンド(アプレピタント)、その他)
・化学療法による悪心&嘔吐治療の用途別市場規模と予測2016-2027(急性悪心&嘔吐治療、遅発性悪心&嘔吐治療、予期性悪心&嘔吐治療)
・化学療法による悪心&嘔吐治療の北米市場規模2016-2027(アメリカ、カナダ)
・化学療法による悪心&嘔吐治療の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・化学療法による悪心&嘔吐治療のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・化学療法による悪心&嘔吐治療の中南米市場規模2016-2027(メキシコ、ブラジル)
・化学療法による悪心&嘔吐治療の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(GlaxoSmithKline、Helsinn、Heron Therapeutics、Merck & Co、Tesaro、Acacia Pharma、Aphios、Barr Laboratories、Baxter Healthcare、Eisai、Especificos Stendhal、F.Hoffmann La Roche、Mundipharma、Mylan Pharmaceuticals、OPKO Health、Orchid Healthcare)
・結論

Market Analysis and Insights: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market
The global Chemotheraphy-induced Nausea and Vomitting Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chemotheraphy-induced Nausea and Vomitting Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chemotheraphy-induced Nausea and Vomitting Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chemotheraphy-induced Nausea and Vomitting Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chemotheraphy-induced Nausea and Vomitting Treatment market.

Global Chemotheraphy-induced Nausea and Vomitting Treatment Scope and Market Size
Chemotheraphy-induced Nausea and Vomitting Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotheraphy-induced Nausea and Vomitting Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Aloxi (Palonosetron)
Kytril (Granisetron)
Emend (Aprepitant)
Others

Segment by Application
Acute Nausea and Vomitting Treatment
Delayed Nausea and Vomitting Treatment
Anticipatory Nausea and Vomitting Treatment

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck & Co
Tesaro
Acacia Pharma
Aphios
Barr Laboratories
Baxter Healthcare
Eisai
Especificos Stendhal
F.Hoffmann La Roche
Mundipharma
Mylan Pharmaceuticals
OPKO Health
Orchid Healthcare

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Aloxi (Palonosetron)
1.2.3 Kytril (Granisetron)
1.2.4 Emend (Aprepitant)
1.2.5 Others
1.3 Market by Application
1.3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Acute Nausea and Vomitting Treatment
1.3.3 Delayed Nausea and Vomitting Treatment
1.3.4 Anticipatory Nausea and Vomitting Treatment
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Perspective (2016-2027)
2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Growth Trends by Regions
2.2.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Dynamic
2.3.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Trends
2.3.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
2.3.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
2.3.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue
3.1.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue (2016-2021)
3.1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue
3.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio
3.4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in 2020
3.5 Chemotheraphy-induced Nausea and Vomitting Treatment Key Players Head office and Area Served
3.6 Key Players Chemotheraphy-induced Nausea and Vomitting Treatment Product Solution and Service
3.7 Date of Enter into Chemotheraphy-induced Nausea and Vomitting Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Type
4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Type (2016-2021)
4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2022-2027)

5 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Application
5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Application (2016-2021)
5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
6.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
6.2.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
6.2.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
6.2.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
6.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
6.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
6.3.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
6.3.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
6.4 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
6.4.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
6.4.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
7.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
7.2.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
7.2.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
7.2.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
7.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
7.3.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
7.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
7.3.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
7.4 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
7.4.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
7.4.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
8.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
8.2.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
8.3.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region
8.4.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
9.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
9.2.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
9.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
9.3.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
9.4 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
9.4.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2016-2027)
10.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
10.2.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
10.3.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
10.4.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.1.4 GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.1.5 GlaxoSmithKline Recent Development
11.2 Helsinn
11.2.1 Helsinn Company Details
11.2.2 Helsinn Business Overview
11.2.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.2.4 Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.2.5 Helsinn Recent Development
11.3 Heron Therapeutics
11.3.1 Heron Therapeutics Company Details
11.3.2 Heron Therapeutics Business Overview
11.3.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.3.4 Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.3.5 Heron Therapeutics Recent Development
11.4 Merck & Co
11.4.1 Merck & Co Company Details
11.4.2 Merck & Co Business Overview
11.4.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.4.4 Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.4.5 Merck & Co Recent Development
11.5 Tesaro
11.5.1 Tesaro Company Details
11.5.2 Tesaro Business Overview
11.5.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.5.4 Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.5.5 Tesaro Recent Development
11.6 Acacia Pharma
11.6.1 Acacia Pharma Company Details
11.6.2 Acacia Pharma Business Overview
11.6.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.6.4 Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.6.5 Acacia Pharma Recent Development
11.7 Aphios
11.7.1 Aphios Company Details
11.7.2 Aphios Business Overview
11.7.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.7.4 Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.7.5 Aphios Recent Development
11.8 Barr Laboratories
11.8.1 Barr Laboratories Company Details
11.8.2 Barr Laboratories Business Overview
11.8.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.8.4 Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.8.5 Barr Laboratories Recent Development
11.9 Baxter Healthcare
11.9.1 Baxter Healthcare Company Details
11.9.2 Baxter Healthcare Business Overview
11.9.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.9.4 Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.9.5 Baxter Healthcare Recent Development
11.10 Eisai
11.10.1 Eisai Company Details
11.10.2 Eisai Business Overview
11.10.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.10.4 Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.10.5 Eisai Recent Development
11.11 Especificos Stendhal
11.11.1 Especificos Stendhal Company Details
11.11.2 Especificos Stendhal Business Overview
11.11.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.11.4 Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.11.5 Especificos Stendhal Recent Development
11.12 F.Hoffmann La Roche
11.12.1 F.Hoffmann La Roche Company Details
11.12.2 F.Hoffmann La Roche Business Overview
11.12.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.12.4 F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.12.5 F.Hoffmann La Roche Recent Development
11.13 Mundipharma
11.13.1 Mundipharma Company Details
11.13.2 Mundipharma Business Overview
11.13.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.13.4 Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.13.5 Mundipharma Recent Development
11.14 Mylan Pharmaceuticals
11.14.1 Mylan Pharmaceuticals Company Details
11.14.2 Mylan Pharmaceuticals Business Overview
11.14.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.14.4 Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.14.5 Mylan Pharmaceuticals Recent Development
11.15 OPKO Health
11.15.1 OPKO Health Company Details
11.15.2 OPKO Health Business Overview
11.15.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.15.4 OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.15.5 OPKO Health Recent Development
11.16 Orchid Healthcare
11.16.1 Orchid Healthcare Company Details
11.16.2 Orchid Healthcare Business Overview
11.16.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.16.4 Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
11.16.5 Orchid Healthcare Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Aloxi (Palonosetron)
Table 3. Key Players of Kytril (Granisetron)
Table 4. Key Players of Emend (Aprepitant)
Table 5. Key Players of Others
Table 6. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Regions (2016-2021)
Table 10. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Regions (2022-2027)
Table 12. Chemotheraphy-induced Nausea and Vomitting Treatment Market Trends
Table 13. Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
Table 14. Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
Table 15. Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints
Table 16. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Players (2016-2021)
Table 18. Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment as of 2020)
Table 19. Ranking of Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Chemotheraphy-induced Nausea and Vomitting Treatment Product Solution and Service
Table 23. Date of Enter into Chemotheraphy-induced Nausea and Vomitting Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. GlaxoSmithKline Company Details
Table 64. GlaxoSmithKline Business Overview
Table 65. GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 66. GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 67. GlaxoSmithKline Recent Development
Table 68. Helsinn Company Details
Table 69. Helsinn Business Overview
Table 70. Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 71. Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 72. Helsinn Recent Development
Table 73. Heron Therapeutics Company Details
Table 74. Heron Therapeutics Business Overview
Table 75. Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 76. Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 77. Heron Therapeutics Recent Development
Table 78. Merck & Co Company Details
Table 79. Merck & Co Business Overview
Table 80. Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 81. Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 82. Merck & Co Recent Development
Table 83. Tesaro Company Details
Table 84. Tesaro Business Overview
Table 85. Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 86. Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 87. Tesaro Recent Development
Table 88. Acacia Pharma Company Details
Table 89. Acacia Pharma Business Overview
Table 90. Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 91. Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 92. Acacia Pharma Recent Development
Table 93. Aphios Company Details
Table 94. Aphios Business Overview
Table 95. Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 96. Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 97. Aphios Recent Development
Table 98. Barr Laboratories Company Details
Table 99. Barr Laboratories Business Overview
Table 100. Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 101. Barr Laboratories Recent Development
Table 102. Baxter Healthcare Company Details
Table 103. Baxter Healthcare Business Overview
Table 104. Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 105. Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 106. Baxter Healthcare Recent Development
Table 107. Eisai Company Details
Table 108. Eisai Business Overview
Table 109. Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 110. Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 111. Eisai Recent Development
Table 112. Especificos Stendhal Company Details
Table 113. Especificos Stendhal Business Overview
Table 114. Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 115. Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 116. Especificos Stendhal Recent Development
Table 117. F.Hoffmann La Roche Company Details
Table 118. F.Hoffmann La Roche Business Overview
Table 119. F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 120. F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 121. F.Hoffmann La Roche Recent Development
Table 122. Mundipharma Company Details
Table 123. Mundipharma Business Overview
Table 124. Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 125. Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 126. Mundipharma Recent Development
Table 127. Mylan Pharmaceuticals Company Details
Table 128. Mylan Pharmaceuticals Business Overview
Table 129. Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 130. Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 131. Mylan Pharmaceuticals Recent Development
Table 132. OPKO Health Company Details
Table 133. OPKO Health Business Overview
Table 134. OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 135. OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 136. OPKO Health Recent Development
Table 137. Orchid Healthcare Company Details
Table 138. Orchid Healthcare Business Overview
Table 139. Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 140. Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021) & (US$ Million)
Table 141. Orchid Healthcare Recent Development
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type: 2020 VS 2027
Figure 2. Aloxi (Palonosetron) Features
Figure 3. Kytril (Granisetron) Features
Figure 4. Emend (Aprepitant) Features
Figure 5. Others Features
Figure 6. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application: 2020 VS 2027
Figure 7. Acute Nausea and Vomitting Treatment Case Studies
Figure 8. Delayed Nausea and Vomitting Treatment Case Studies
Figure 9. Anticipatory Nausea and Vomitting Treatment Case Studies
Figure 10. Chemotheraphy-induced Nausea and Vomitting Treatment Report Years Considered
Figure 11. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Regions: 2020 VS 2027
Figure 14. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Regions (2022-2027)
Figure 15. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Players in 2020
Figure 16. Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in 2020
Figure 18. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2016-2021)
Figure 19. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2022-2027)
Figure 20. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2016-2027)
Figure 22. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2016-2027)
Figure 23. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2016-2027)
Figure 24. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2016-2027)
Figure 28. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2016-2027)
Figure 29. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2016-2027)
Figure 30. Germany Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2016-2027)
Figure 40. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2016-2027)
Figure 48. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2016-2027)
Figure 49. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2016-2027)
Figure 50. Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2016-2027)
Figure 56. Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. GlaxoSmithKline Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 60. Helsinn Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 61. Heron Therapeutics Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 62. Merck & Co Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 63. Tesaro Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 64. Acacia Pharma Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 65. Aphios Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 66. Barr Laboratories Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 67. Baxter Healthcare Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 68. Eisai Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 69. Especificos Stendhal Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 70. F.Hoffmann La Roche Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 71. Mundipharma Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 72. Mylan Pharmaceuticals Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 73. OPKO Health Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 74. Orchid Healthcare Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed